Company Description
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
The company was incorporated in 2016 and is based in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 236 |
| CEO | Brian Thomas |
Contact Details
Address: 5959 Horton Street, 7th Floor EmeryVille, California 94608 United States | |
| Phone | 510 871 4880 |
| Website | metagenomi.co |
Stock Details
| Ticker Symbol | MGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001785279 |
| ISIN Number | US59102M1045 |
| Employer ID | 81-3909017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Dr. Jian Irish M.B.A., Ph.D. | President, Chief Operating Officer and Director |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer |
| Dr. Joseph Knowles M.D. | Co-Founder and Member of Scientific Advisory Board |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Simon Harnest M.Sc. | Chief Investment Officer and Senior Vice President of Investor Relations |
| Matthew L. Wein J.D. | Vice President of Corporate Legal, Compliance and Corporate Secretary |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Preclinical |
| Dr. Christopher Brown | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |